HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone.

Abstract
The aim of this paper was to investigate whether rotenone, a pesticide causing experimental parkinsonism, causes direct damage to dopaminergic structure when injected intracerebrally and whether this action may be prevented by peripheral administration of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), an endogenous compound with anti-dopaminergic activity. Male Wistar rats were injected unilaterally into the median forebrain bundle with 2 microg rotenone, and received 1MeTIQ, 50 mg/kg i.p. 1 h before and then daily for 21 d. To compare the effect of intracerebral and peripheral treatment, rotenone was also given once or for 7 d in a dose of 10 mg/kg s.c. Dopamine, serotonin and their metabolites were assessed by HPLC in the substantia nigra and striatum. While a single subcutaneous rotenone dose did not produce any change in striatal dopamine metabolism, the multiple treatments resulted in changes suggesting a shift in the metabolism towards oxidative desamination and reduction of O-methylation. In contrast to systemic injections, intracerebral-administered rotenone produced a decrease in dopamine and its metabolites content in the striatum (dopamine decrease by 70%) and substantia nigra (dopamine decrease by 35%), without affecting the serotonin system. As those changes were observed 21 d after the injection of rotenone, they suggest a durable neurotoxic effect. The treatment with 1MeTIQ strongly reduced the fall of striatal dopamine concentration. The data suggest that rotenone given peripherally affects metabolic processes in dopaminergic neurons, and this seems to result from its neurotoxic action, which may be observed after an intracerebral injection. 1MeTIQ is able to counteract the damaging action of rotenone and seems to be a potential neuroprotective agent.
AuthorsLucyna Antkiewicz-Michaluk, Jadwiga Wardas, Jerzy Michaluk, Irena Romaska, Andrzej Bojarski, Jerzy Vetulani
JournalThe international journal of neuropsychopharmacology (Int J Neuropsychopharmacol) Vol. 7 Issue 2 Pg. 155-63 (Jun 2004) ISSN: 1461-1457 [Print] England
PMID14741061 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Neuroprotective Agents
  • Tetrahydroisoquinolines
  • Uncoupling Agents
  • Rotenone
  • Serotonin
  • 1-methyl-1,2,3,4-tetrahydroisoquinoline
  • Dopamine
Topics
  • Animals
  • Basal Ganglia Diseases (chemically induced, pathology, prevention & control)
  • Brain Chemistry (drug effects)
  • Dopamine (metabolism, physiology)
  • Injections
  • Injections, Subcutaneous
  • Male
  • Medial Forebrain Bundle
  • Neostriatum (drug effects, metabolism)
  • Nerve Degeneration (chemically induced, pathology, prevention & control)
  • Neuroprotective Agents (therapeutic use)
  • Presynaptic Terminals (drug effects, pathology)
  • Rats
  • Rats, Wistar
  • Rotenone (administration & dosage, antagonists & inhibitors, toxicity)
  • Serotonin (metabolism)
  • Stereotaxic Techniques
  • Substantia Nigra (drug effects, metabolism)
  • Tetrahydroisoquinolines (therapeutic use)
  • Uncoupling Agents (administration & dosage, antagonists & inhibitors, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: